These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31850802)

  • 1. Reaching blood pressure guideline targets with the CNIC polypill in patients with a previous cardiovascular event in Mexico: a
    Gómez-Álvarez E; Verdejo J; Ocampo S; Ruiz E; Martinez-Rios MA
    Future Cardiol; 2020 Jan; 16(1):53-60. PubMed ID: 31850802
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study.
    Castellano JM; Verdejo J; Ocampo S; Rios MM; Gómez-Álvarez E; Borrayo G; Ruiz E; Ibáñez B; Fuster V;
    Arch Med Res; 2019 Jan; 50(1):31-40. PubMed ID: 31101241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study.
    González-Juanatey JR; Cordero A; Castellano JM; Masana L; Dalmau R; Ruiz E; Sicras-Mainar A; Fuster V
    Int J Cardiol; 2022 Aug; 361():116-123. PubMed ID: 35569611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CNIC-polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease.
    Dalmau R; Cordero A; Masana L; Ruiz E; Sicras-Mainar A; González-Juanatey JR
    Eur Heart J Open; 2024 Mar; 4(2):oeae027. PubMed ID: 38686352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of combination therapy for achieving goal blood pressure in high CV risk patients.
    Cardiovasc J S Afr; 2001; 12(1):54-5. PubMed ID: 11474688
    [No Abstract]   [Full Text] [Related]  

  • 7. Association between cardiovascular outcomes and antihypertensive drug treatment in older women.
    Wassertheil-Smoller S; Psaty B; Greenland P; Oberman A; Kotchen T; Mouton C; Black H; Aragaki A; Trevisan M
    JAMA; 2004 Dec; 292(23):2849-59. PubMed ID: 15598916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?
    González-Juanatey JR; Tamargo J; Torres F; Weisser B; Oudovenko N
    Rev Esp Cardiol (Engl Ed); 2021 Jan; 74(1):51-58. PubMed ID: 31983653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension.
    Coca A; Kreutz R; Manolis AJ; Mancia G
    J Hypertens; 2020 Oct; 38(10):1890-1898. PubMed ID: 32890261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fixed-drug combinations for hypertension].
    Sato N; Hasebe N
    Nihon Rinsho; 2014 Aug; 72(8):1477-84. PubMed ID: 25167756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial.
    Mostaza JM; Suárez-Fernández C; Cosín-Sales J; Gómez-Huelgas R; Brotons C; Araujo FP; Borrayo G; Ruiz E;
    BMC Cardiovasc Disord; 2022 Dec; 22(1):560. PubMed ID: 36550424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials.
    Selak V; Webster R; Stepien S; Bullen C; Patel A; Thom S; Arroll B; Bots ML; Brown A; Crengle S; Dorairaj P; Elley CR; Grobbee DE; Harwood M; Hillis GS; Laba TL; Neal B; Peiris D; Rafter N; Reid C; Stanton A; Tonkin A; Usherwood T; Wadham A; Rodgers A
    Heart; 2019 Jan; 105(1):42-48. PubMed ID: 29954855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of the CNIC polypill in secondary cardiovascular prevention in the subgroup of patients of the NEPTUNO study using atorvastatin doses of 20 mg].
    González-Juanatey JR; Cordero A; Masana L; Dalmau R
    Arch Cardiol Mex; 2024 Jun; ():. PubMed ID: 38843861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension.
    Morgan TO; Anderson AI; MacInnis RJ
    Am J Hypertens; 2001 Mar; 14(3):241-7. PubMed ID: 11281235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy as first-line treatment for hypertension.
    Crawford MH
    Am J Cardiovasc Drugs; 2009; 9(1):1-6. PubMed ID: 19178127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
    Tytus RH; Burgess ED; Assouline L; Vanjaka A
    Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain.
    González-Domínguez A; Durán A; Hidalgo-Vega Á; Barrios V
    Rev Clin Esp (Barc); 2023; 223(7):414-422. PubMed ID: 37352973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.
    Turnbull F;
    Lancet; 2003 Nov; 362(9395):1527-35. PubMed ID: 14615107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.